AU2001238034A1 - Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) - Google Patents

Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Info

Publication number
AU2001238034A1
AU2001238034A1 AU2001238034A AU3803401A AU2001238034A1 AU 2001238034 A1 AU2001238034 A1 AU 2001238034A1 AU 2001238034 A AU2001238034 A AU 2001238034A AU 3803401 A AU3803401 A AU 3803401A AU 2001238034 A1 AU2001238034 A1 AU 2001238034A1
Authority
AU
Australia
Prior art keywords
disease
apc
diseases
vascular
activated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238034A
Other languages
English (en)
Inventor
John H Griffin
Berislav Y. Zlokovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
University of Southern California USC
Original Assignee
Scripps Research Institute
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, University of Southern California USC filed Critical Scripps Research Institute
Publication of AU2001238034A1 publication Critical patent/AU2001238034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001238034A 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) Abandoned AU2001238034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18022700P 2000-02-04 2000-02-04
US60/180,227 2000-02-04
PCT/US2001/003758 WO2001056532A2 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Publications (1)

Publication Number Publication Date
AU2001238034A1 true AU2001238034A1 (en) 2001-08-14

Family

ID=22659693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238034A Abandoned AU2001238034A1 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Country Status (8)

Country Link
US (1) US7074402B2 (enExample)
EP (1) EP1255556B1 (enExample)
JP (1) JP2004508280A (enExample)
AT (1) ATE504310T1 (enExample)
AU (1) AU2001238034A1 (enExample)
CA (1) CA2398929C (enExample)
DE (1) DE60144366D1 (enExample)
WO (1) WO2001056532A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
ATE550073T1 (de) 2001-06-13 2012-04-15 Univ Sydney Protein c für die wundheilung
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
CA2499458C (en) * 2002-09-30 2013-11-12 Socratech L.L.C. Protein s protects the nervous system from injury
CA2508276C (en) * 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
AU2008280782B2 (en) 2007-07-20 2014-01-23 Diamedica Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions
CN102458454A (zh) * 2009-04-22 2012-05-16 森诺姆尼有限公司 用于治疗亨廷顿病的组织激肽释放酶
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
CN104122396A (zh) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 维生素k依赖性蛋白s作为糖尿病标志物的应用
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
CN105806818B (zh) * 2016-04-01 2019-11-22 南京医科大学 检测血小板nmda受体活性的方法及其应用
WO2017212476A1 (en) 2016-06-05 2017-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Novel molecules for the treatment of inflammation
KR20190122706A (ko) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
CA3176941A1 (en) * 2020-03-24 2021-09-30 Talengen International Limited Method and medicine for treating huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL131615A0 (en) * 1997-03-24 2001-01-28 Lilly Co Eli Methods for treating vascular disorders
CN1265598A (zh) * 1997-06-05 2000-09-06 伊莱利利公司 治疗血栓形成性疾病的方法
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP1255556A4 (en) 2003-07-02
CA2398929C (en) 2011-05-31
WO2001056532A2 (en) 2001-08-09
JP2004508280A (ja) 2004-03-18
DE60144366D1 (de) 2011-05-19
WO2001056532A3 (en) 2001-12-06
CA2398929A1 (en) 2001-08-09
ATE504310T1 (de) 2011-04-15
US20020028199A1 (en) 2002-03-07
US7074402B2 (en) 2006-07-11
EP1255556A2 (en) 2002-11-13
EP1255556B1 (en) 2011-04-06
WO2001056532A9 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
AU2001238034A1 (en) Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
WO2004110389A3 (en) Sigma ligands for neuronal regeneration and functional recovery
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO2002043652A3 (en) Anti-proliferative drugs
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
CA2029065A1 (en) Method of treating anxiety related disorders using sertraline
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
PL1703902T3 (pl) Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2007053580A3 (en) Sigma ligands for neuronal regeneration and functional recovery
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
EP1365771A4 (en) METHOD OF TREATING CERTAIN EYE DISEASES
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
WO2021222263A3 (en) Compositions and methods for treating inflammasome related diseases or conditions
WO2023107630A3 (en) Amino alcohol compounds and uses thereof